Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (K d : 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
IC50 & Target[1][2]
IC50: DR5 (<1 nM)
体外研究(In Vitro)
Conatumumab (0-10 μg/mL,4 小时) 激活 Colo205、H-2122 和 MiaPaCa2 细胞中的 caspase-3/7。Conatumumab (0-10 μg/mL,24 小时) 降低敏感肿瘤细胞系 (Colo205、H-2122 和 MiaPaCa2 细胞) 的细胞活力。 has not independently confirmed the accuracy of these methods. They are for reference only.Cell Viability Assay
体内研究(In Vivo)
Conatumumab (0-100 μg,腹腔注射,每周两次) 抑制 Colo205、H2122 或 MiaPaCa2/T2 异种移植肿瘤的小鼠的肿瘤生长。
Conatumumab (2.5 μg,i.p.,每周 3 次) 增强化疗药物 (CPT11,HY- 16562) (80 mg/kg) 在 Colo 205 移植瘤中的抗肿瘤活性。 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91. [2]. Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9(8):618-31.